SAN DIEGO, Aug. 31, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (“Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that its wholly-owned subsidiary, NexMed USA, Inc., has received clearance from the U.S. Food and Drug Administration (“FDA”) for its third, over-the-counter (“OTC”) drug, Diphenhydramine-D™, containing the Company’s NexACT® technology.
